The Global Blooming (TGB) is advancing Project 1102 centered on BNCT (Boron Neutron Capture Therapy). Led by a drug-discovery expert and a world-class team, we are building a drug × platform that enables highly selective retention of boron carriers in target cells (including cancer cells). Our aim is practical implementation focused on refractory cancers, rejuvenation, and regenerative medicine.
News: On August 25, 2025, Project 1102 was publicly announced as selected for JETRO’s “Subsidy for Projects to Stimulate Direct Investment in Japan”. This support will accelerate our R&D and international collaboration.
Why BNCT
- Simple: Physically destroys complex therapeutic targets whose organ- and intracellular mechanisms are difficult to modulate pharmacologically.
- Combination therapy: Flexible options to combine with other therapeutics.
- Selectivity: Neutron irradiation targets cells that have accumulated boron isotopes, aiming to destroy cancer cells while sparing others.
- Lower patient burden: Provides options where surgery or standard care is limited.
- Unmet needs: High demand to balance efficacy and quality of life in hard-to-treat areas such as head and neck cancers.
- Minimizing animal experiments: A development scheme that supports reduction of animal use—an increasingly prioritized regulatory perspective—via direct physical mechanisms and verifiable testing.
Our Approach (Drug × Platform)
- Carrier design: Integrated optimization of specificity, intracellular retention, and safety for target cells.
- Delivery optimization: Multilayer optimization informed by the tumor microenvironment and cellular kinetics.
- Protocol integration: Clinic-minded design aligned with dosing and irradiation conditions.
- Platformization: A cross-functional foundation connecting molecule design, preclinical evaluation, and data governance.
Focus Areas (Specialization & Applications)
- Refractory cancers: Focus on indications where current therapies have limited benefit.
- Rejuvenation: Exploration of strategies to modulate age-related target cell populations.
- Regenerative medicine: Evaluation of selective control of inhibitory cell groups and potential preconditioning use cases.
Operating Structure
- Lead: The Global Blooming (TGB) / Project 1102
- Collaboration: National research institutes and universities in Japan, and academia/biotechs in Europe and the U.S. (in developing)
- R&D Stage: Drug discovery & platform building
Partner Selection
Project 1102 is not a device-development project. However, co-design and co-implementation with optimal irradiation-system manufacturers is critical for real-world deployment.
- Who we work with: Irradiation-system manufacturers, biopharma/biotech, medical institutions, and universities
- Scope: Preclinical validation, implementation-protocol design, and regulatory/quality readiness as collaborative implementation partners
Key Differentiation
- Retention-centric drug design: A triad of specificity, persistence, and safety, enhanced by AI-assisted design.
- Execution-driven decisions: Rapid, pragmatic validation led by a drug-discovery expert with a world-class team.
- Historically grounded insight & empirical reasoning: Practical data interpretation and project execution that avoid the common pitfalls of generative AI.
- Platform mindset: Data-driven reproducibility and extensibility from R&D to implementation.
Related Pages
Disclaimer: This page is for R&D information and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals.